ANGELS
- Conditions
- Type 2 Diabetes Mellitus
- Registration Number
- JPRN-jRCTs041180085
- Lead Sponsor
- Arima Hiroshi
- Brief Summary
This study showed that the DPP-4 inhibitor anagliptin reduces fasting apolipoprotein B-48 levels, suggesting that this drug may have beneficial effects on lipid metabolism possibly mediated by the inhibition of intestinal lipid transport.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 24
Type 2 diabetes
HbA1c >= 6.5%
Serum LDL >= 120 mg/dl
No DPP4 inhibitors for latest 3 months
No antidiabetic medication or no change in medication for the latest 3 months
20 y.o. or older
Written agreement is obtainable from the patient
Type 1 diabetes
Treatment with insulin, glinides, high doses of SU
Patients with repetitive or unaware severe hypoglycemia
Severe liver diseases
Patients with hemodialysis
Severe cardiac diseases or acute myocardial infarction within 6 months
Severe anemia
Severe pancreatitis
Malignant diseases
Uncontrolled endocrine diseases
Severe infections or surgical treatment
Severe diabetic complications
Severe bowel diseases
Alcohol addiction
Pregnant or possibly pregnant women
History of allergic reaction to DPP4 inhibitors
Patients who a physician-in-charge considers is unsuitable for the trial.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Blood lipid fractions
- Secondary Outcome Measures
Name Time Method HbA1c, inflammatory marker, oxidative stress marker, cytokine